A randomized, open labeled study comparing the serum levels of cobalamin after three doses of 500 mcg vs. a single dose methylcobalamin of 1500 mcg in patients with peripheral neuropathy
10.3344/kjp.2018.31.3.183
- Author:
Amrita SIL
1
;
Hrishikesh KUMAR
;
Rahul Deb MONDAL
;
Sidharth Sankar ANAND
;
Anirban GHOSAL
;
Ashis DATTA
;
Sandesh V SAWANT
;
Vaibhavi KAPATKAR
;
Ganesh KADHE
;
Sameer RAO
Author Information
1. Department of Pharmacology, IPGME&R, Kolkata, India. drsilamrita@gmail.com
- Publication Type:Comparative Study
- Keywords:
Clinical protocols;
Cobalamin (vitamin B12);
Drug dose-response relationship;
Intramuscular injection;
Methylcobalamin;
Neuropathic pain;
Peripheral neuropathy;
Prospective studies;
Randomized controlled clinical trials;
Survey and questionnaire;
Vitamin B12 deficiency
- MeSH:
Clinical Protocols;
Dose-Response Relationship, Drug;
Healthy Volunteers;
Humans;
Injections, Intramuscular;
Lower Extremity;
Neuralgia;
Peripheral Nerves;
Peripheral Nervous System Diseases;
Prospective Studies;
Sensation;
Vitamin B 12 Deficiency;
Vitamin B 12
- From:The Korean Journal of Pain
2018;31(3):183-190
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Vitamin B12 deficiency has been associated with peripheral neuropathy, loss of sensation in the peripheral nerves, and weakness in the lower extremities. Methylcobalamin is the most effective analogue of vitamin B12 used to treat or prevent the complications associated with vitamin B12 deficiency. The current study aimed to compare the serum cobalamin levels after administration of two different regimes of methylcobalamin in peripheral neuropathy patients. METHODS: The present study was a prospective, randomized, comparative study. The study consisted of two parallel groups, group A (methylcobalamin 500 µg injection intramuscularly three times a week) and group B (methylcobalamin 1500 µg injection intramuscularly once a week). A control group of healthy volunteers was also included. RESULTS: A total of 24 patients (12 in each group) were included in the study. Five healthy volunteers were also included as a control in each group. At the end of treatment, serum cobalamin levels were significantly (P = 0.028) higher in group A (1892.08 ± 234.50) as compared with group B (1438.5 ± 460.32). The serum cobalamin levels in Group A healthy volunteers were also two times higher than that of group B (P = 0.056). Both the LANSS scale and DN4 questionnaire reported similar results at end of treatment. CONCLUSIONS: The 500 µg methylcobalamin thrice weekly regime is more effective in increasing the serum cobalamin levels as compared to the 1500 µg methylcobalamin once weekly regime.
